600645.SH
中源协和
SSE · Healthcare · Biotechnology · CN
CNY 19.23
−3.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.5B | 1.6B | 1.6B | 1.6B |
| Cost of Revenue | 424.2M | 438.8M | 487.7M | 491.4M | 503.0M |
| Gross Profit | 997.3M | 1.0B | 1.1B | 1.1B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 146.1M | 149.0M | 182.1M | 184.5M | 147.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 349.9M | 349.7M | 349.1M | 350.9M | 334.4M |
| Selling & Marketing Expense | 293.1M | 305.1M | 350.3M | 373.9M | 392.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 794.0M | 807.0M | 885.0M | 901.8M | 878.7M |
| Cost and Expenses | 1.2B | 1.2B | 1.4B | 1.4B | 1.4B |
| Operating Income (EBIT) | 178.7M | 177.6M | 135.8M | 131.1M | 156.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 175.5M | 174.4M | 135.9M | 132.6M | 155.2M |
| Income Tax Expense | 73.3M | 70.9M | 46.6M | 34.0M | 48.5M |
| Bottom Line | |||||
| Net Income | 110.0M | 113.8M | 100.4M | 106.5M | 113.0M |
| Earnings from Cont. Ops | 102.1M | 103.5M | 89.4M | 98.6M | 106.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 110.0M | 113.8M | 100.4M | 106.5M | 113.0M |
| Per Share | |||||
| Basic EPS | CN¥0.24 | CN¥0.25 | CN¥0.22 | CN¥0.23 | CN¥0.24 |
| Diluted EPS | CN¥0.24 | CN¥0.25 | CN¥0.22 | CN¥0.23 | CN¥0.24 |
| Revenue Per Share | CN¥2.93 | CN¥3.20 | CN¥3.48 | CN¥3.43 | CN¥3.30 |
| Shares | |||||
| Basic Shares Outstanding | 484.9M | 455.3M | 456.1M | 462.8M | 470.8M |
| Diluted Shares Outstanding | 484.9M | 455.3M | 456.1M | 462.8M | 470.8M |
| Profitability Metrics | |||||
| EBITDA | — | 342.6M | 305.9M | 303.7M | 292.9M |
| D&A | — | 165.0M | 170.1M | 172.6M | 136.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026